午夜一区二区三区不卡视频_丁香色婷婷国产精品视频_一本在线视频在线观看_色婷婷五月最新网站

Hot:

New Blueprint for Overseas Markets | Kernel Medical Enters Strategic Partnership with Dr. Reddy's

Data:2024-07-03     Author:KernelMed     Views:

On a golden autumn day in Shanghai, the 6th China International Import Expo (CIIE) took place as scheduled. On November 7, Kernel Medical Equipment Co., Ltd. (hereinafter referred to as "Kernel Medical") and Dr. Reddy's Laboratories Ltd. (hereinafter referred to as "Dr. Reddy's") met at the expo and held a strategic cooperation signing ceremony, where both parties agreed to jointly explore overseas markets, including India.

圖片.png

The signing ceremony was attended by Zhao Wei, Chairman of Kernel Medical; Zhang Zhengjun, R&D Director; Fu Dawei, Director of the Overseas Business Department; Erez Israeli, Global CEO of Dr. Reddy's; M.V. Ramana, CEO of India and Emerging Markets; Satheesh, General Manager for China; Pankaj, Head of BD for India and Emerging Markets; and other relevant team members from both sides. Together, they witnessed the beginning of a new chapter in their collaboration.

圖片.png

This partnership signifies Kernel Medical's increased commitment to expanding into overseas markets, injecting new momentum into the company’s international business growth and development. Kernel Medical and Dr. Reddy's share numerous synergistic points in the field of smart healthcare. This collaboration marks the start of a continued effort by both companies to leverage their respective strengths in smart medical products, innovative technologies, overseas resources, and distribution channels. Together, they aim to broaden the scope of their cooperation and bring safer and more effective treatment options and solutions to patients in India and beyond.

圖片.png

圖片.png

For 26 years, Kernel Medical has been focused on becoming a technology and product-driven company, adhering to rigorous R&D standards, and placing innovation and user experience at the core of its mission. Kernel Medical is dedicated to developing high-value, high-quality, intelligent medical products. Moving forward, the company will continue to emphasize both independent research and development as well as open collaboration. By working closely with outstanding domestic and international enterprises, Kernel Medical will fully leverage its advantages, continually explore global markets, and contribute more to safeguarding human health.

圖片.png

圖片.png

Kernel Medical, established in 1997, specializes in products for dermatology, gynecology, emergency care, and monitoring. Since its inception, Kernel has adhered to its mission of “Leading with Technology, Committing to Life.” The company was the first in the industry to introduce innovative medical products such as the LED ultraviolet phototherapy device, video Wood's lamp, and multi-light source photodynamic therapy device. In the field of ultraviolet phototherapy devices, Kernel has pioneered the application of the electronic prescription concept, introduced DC technology in this product category for the first time, and achieved the highest international standards. It is the only product that has gained market access in major regions, including the United States, the European Union, and China. Kernel’s products, including ultraviolet phototherapy devices, LED spectrum therapy devices, and photoelectric colposcopes, lead the industry in terms of product range, technological innovation, and service quality, making it a true industry leader.

圖片.png

Dr. Reddy's, founded in 1984, is a publicly traded global pharmaceutical company headquartered in Hyderabad, India. It is listed on the New York Stock Exchange (NYSE: RDY), the National Stock Exchange of India (NSE: DRREDDY), and the Bombay Stock Exchange (BSE: 500124). The company’s products and services span a wide range of therapeutic areas, including Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, Proprietary Products, and Biosimilars. Driven by its commitment to accelerating access to affordable and innovative medicines, Dr. Reddy's continuously seeks to enter new therapeutic areas to address unmet medical needs worldwide, because “Good Health Can’t Wait.”